[{"address1": "1050 Waltham Street", "address2": "Suite 302", "city": "Lexington", "state": "MA", "zip": "02421", "country": "United States", "phone": "617 314 6297", "website": "https://www.kerostx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.", "fullTimeEmployees": 141, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jasbir S. Seehra Ph.D.", "age": 67, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1125546, "exercisedValue": 158640, "unexercisedValue": 29544660}, {"maxAge": 1, "name": "Mr. Keith C. Regnante MBA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 636108, "exercisedValue": 1224174, "unexercisedValue": 2436540}, {"maxAge": 1, "name": "Mr. Christopher  Rovaldi M.Sc.", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 784900, "exercisedValue": 0, "unexercisedValue": 260100}, {"maxAge": 1, "name": "Ms. Esther  Cho J.D.", "title": "Senior VP, General Counsel & Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Robin  Wagner", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Oram M.B.A.", "title": "Senior Vice President of Program & Portfolio Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 43.77, "open": 43.46, "dayLow": 42.39, "dayHigh": 43.81, "regularMarketPreviousClose": 43.77, "regularMarketOpen": 43.46, "regularMarketDayLow": 42.39, "regularMarketDayHigh": 43.81, "beta": 1.249, "forwardPE": -8.394118, "volume": 330056, "regularMarketVolume": 330056, "averageVolume": 326780, "averageVolume10days": 505310, "averageDailyVolume10Day": 505310, "bid": 42.7, "ask": 42.88, "bidSize": 200, "askSize": 100, "marketCap": 1544751872, "fiftyTwoWeekLow": 27.02, "fiftyTwoWeekHigh": 73.0, "priceToSalesTrailing12Months": 6601.504, "fiftyDayAverage": 51.0418, "twoHundredDayAverage": 47.1552, "currency": "USD", "enterpriseValue": 1116512128, "floatShares": 30946623, "sharesOutstanding": 36083900, "sharesShort": 2606491, "sharesShortPriorMonth": 2426877, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0722, "heldPercentInsiders": 0.060960002, "heldPercentInstitutions": 1.03511, "shortRatio": 9.29, "shortPercentOfFloat": 0.1029, "bookValue": 12.586, "priceToBook": 3.4013984, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -160302000, "trailingEps": -5.15, "forwardEps": -5.1, "pegRatio": -1.16, "enterpriseToRevenue": 4771.419, "enterpriseToEbitda": -6.25, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "KROS", "underlyingSymbol": "KROS", "shortName": "Keros Therapeutics, Inc.", "longName": "Keros Therapeutics, Inc.", "firstTradeDateEpochUtc": 1586352600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a73338e2-0750-36db-8d66-d045f2fcde9f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 42.81, "targetHighPrice": 105.0, "targetLowPrice": 80.0, "targetMeanPrice": 91.89, "targetMedianPrice": 88.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 442443008, "totalCashPerShare": 12.262, "ebitda": -178630000, "totalDebt": 14204000, "quickRatio": 23.732, "currentRatio": 24.742, "totalRevenue": 234000, "debtToEquity": 3.129, "revenuePerShare": 0.007, "returnOnAssets": -0.25791, "returnOnEquity": -0.39633, "freeCashflow": -90178872, "operatingCashflow": -134832992, "operatingMargins": -584.13257, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-03"}]